Sector
PharmaceuticalsOpen
₹700Prev. Close
₹737.95Turnover(Lac.)
₹85.35Day's High
₹737Day's Low
₹69552 Week's High
₹1,069.9552 Week's Low
₹481Book Value
₹233.21Face Value
₹10Mkt Cap (₹ Cr.)
745.48P/E
21.73EPS
33.96Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 10.38 | 10.38 | 10.38 | 10.38 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 215.57 | 191.65 | 172.18 | 52.13 |
Net Worth | 225.95 | 202.03 | 182.56 | 62.51 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Revenue | 261.5 | 138.68 | 165.15 | 136.82 |
yoy growth (%) | 88.56 | -16.02 | 20.7 | 43.54 |
Raw materials | -165.59 | -87.07 | -119.34 | -101.28 |
As % of sales | 63.32 | 62.78 | 72.26 | 74.02 |
Employee costs | -15.67 | -11.68 | -8.42 | -5.53 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 21.79 | 11.14 | 10.89 | 7.55 |
Depreciation | -6.43 | -4.39 | -3.05 | -2.85 |
Tax paid | -6.38 | -2.7 | -3.34 | -2.87 |
Working capital | 3.88 | 11.55 | 1.1 | 6.11 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 88.56 | -16.02 | 20.7 | 43.54 |
Op profit growth | 107.32 | -7.37 | 32.62 | 34.55 |
EBIT growth | 78.98 | 4.05 | 34.65 | 26.66 |
Net profit growth | 82.82 | 11.71 | 61.4 | 35.96 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 307.17 | 251.03 | 456.19 | 262.01 | 139.3 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 307.17 | 251.03 | 456.19 | 262.01 | 139.3 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 1.83 | 2.94 | 3.51 | 1.59 | 3.66 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,766.2 | 134.52 | 4,23,770.54 | 1,181.05 | 0.76 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,958.35 | 76.3 | 1,58,175.47 | 594 | 0.5 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,486.75 | 25.8 | 1,20,075.94 | 1,438.15 | 0.87 | 4,134.87 | 360.72 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,183 | 59.05 | 1,07,722.35 | 485 | 0.88 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,434.1 | 51.93 | 1,00,425.74 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
Ramesh Arora
Whole-time Director
Ajay Arora
Independent Director
Ravi Shanker Singh
Whole-time Director
Geeta Arora
Whole-time Director
Anju Arora
Whole Time Director & CFO
Aditya Arora
Independent Director
Pankaj Takkar
Independent Director
Kiran Kumar Verma
Company Sec. & Compli. Officer
Gurpreet Kaur
Independent Director
Kartik Kapur
Independent Director
Prashanth Vellanki
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Kwality Pharmaceuticals Ltd
Summary
Kwality Pharmaceuticals Limited was Incorporated on May 4th 1983 when its founder Mr. Ramesh Arora was inspired to begin his own venture leaving behind the already flourishing family business of spinning and aromatics. With little background of finished pharmaceuticals and high held spirits and will, he started this business. He received his first drug license in 1981 approved for liquid oral manufacturing. Presently, the Company has 48 different sections available at their production centres.Kwality Pharmaceuticals Ltd. are manufacturer of finished pharmaceutical formulations in a Liquid Orals, Dry Syrups, Tablets, Capsules, Sterile Powder for Injections and small volume injectables. The Company has the most modern & sophisticated Plant, Equipment, technique, and workforce. Certified as ISO: 9001:2015 and ISO 14001:2015, it is working with new SCHEDULE M and WHO norms and certified with GMP. The Company is keeping all records of inputs used in manufacturing. The inputs are tested as per standard laid down by company SOP. The in-process testing records are also maintained as per SOP. Similarly, finished goods are also tested as per SOP and are then allowed for sale. Apart from these, the Company is making medicines in various dosage forms like Liquid Orals, Powder for Oral Suspension, Tablets, Capsules, Dry Syrup, Syrup, Sterile Powder for Injections, small volume injectables, Ointments, External Preparations, ORS and many more in various categories like Beta Lactam & non-Bet
Read More
The Kwality Pharmaceuticals Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹718.45 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Kwality Pharmaceuticals Ltd is ₹745.48 Cr. as of 09 May ‘25
The PE and PB ratios of Kwality Pharmaceuticals Ltd is 21.73 and 3.16 as of 09 May ‘25
The 52-week high/low is the highest and lowest price at which a Kwality Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Kwality Pharmaceuticals Ltd is ₹481 and ₹1069.95 as of 09 May ‘25
Kwality Pharmaceuticals Ltd's CAGR for 5 Years at 83.99%, 3 Years at 21.58%, 1 Year at 48.96%, 6 Month at -20.21%, 3 Month at -3.89% and 1 Month at -9.47%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.